An adaptive platform trial (APT) offers the ability to incorporate several research questions, in the same target population, across multiple domains (interventions), with the ability to add new questions in a perpetual manner. An APT is particularly appealing for paediatric haematopoietic stem cell transplant (HCT); an area of high heterogeneity, limited trial availability and high mortality. Ideally, all domains in an APT, would have the same primary endpoint. Therefore, an ordinal endpoint with multiple categories that combines various clinical outcomes into a single outcome measure is particularly appealing for APTs. Unfortunately there is no accepted ordinal endpoint for paediatric HCT trials. This paper aims to describe the methodology used to co-design a novel primary ordinal endpoint for the paediatric HCT APT - BANDICOOT. BANDICOOT is a study which aims to; "Build an Adaptive Novel platform Design: Improving the Complications, cost-effectiveness, Outcomes and Overall survival from haematopoietic stem cell transplant".The results of this process identified two potential ordinal endpoints that could be used, one focusing on organ support and the other on a combination of organ support, viral reactivation and immune reconstitution. We explored the data extraction required for these endpoints from electronic medical records which we will utilise to validate the endpoints and determine which will be used in the APT BANDICOOT. In an era where APT's are becoming increasingly utilised to answer important questions in clinical care, this article describes a reproducible strategy for the design of high quality and meaningful ordinal endpoints.